Vivian Aghanya

Jan 1, 2024 | jrheum.org | Timothy Kwok |Bindee Kuriya |Lihi Eder |Vivian Aghanya

To the Editor:Individuals with rheumatoid arthritis (RA) may be at increased risk of severe coronavirus disease 2019 (COVID-19) outcomes.1 Nirmatrelvir/ritonavir has been shown to reduce the risk for hospitalization and death among patients with COVID-19 at risk for progression to severe disease.2 On April 4, 2022, nirmatrelvir/ritonavir became available in Ontario, Canada, for high-risk individuals, including immunosuppressed patients with rheumatic disease, such as RA.